RxDoctor Payments Data

Danielle Parker

Acute Care · Littleton, CONPI 1306434824

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $5,500 of the $6,652 with a category attached, or 82.7%. 25 manufacturers reported payments, led by Medtronic at 26.6% of the total. 2025 is the largest year on record at $2,870, 5.4 times the $528 reported in 2021. Among acute care clinicians in CO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,652in general payments, 2019–2025

Across 117 payments — averaging $56.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Boston Scientific$885
  • Amgen$567
  • Cvrx, Inc.$499
  • Novartis$422
  • Impulse Dynamics (USA) Inc.$332
  • plus $2K from 19 others

What the payments were for

  • Travel & lodging$1,10417%
  • Food & beverage$5,50083%
  • Education$481%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,652 in reported general payments places this provider in the 90th percentile of 239 acute care providers in Colorado.

See all acute care providers in Colorado

Medicare billing

Part B allowed, 2024
$65,129
Medicare patients
431
Services billed
944

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban48$57,132
JardianceEmpagliflozin47$56,965
Repatha SureclickEvolocumab67$49,463
OzempicSemaglutide42$40,666
Praluent PenAlirocumab24$17,814
MounjaroTirzepatide16$16,996
EntrestoSacubitril/Valsartan15$9,485
Rosuvastatin Calcium203$2,263
Ezetimibe99$1,533
Prasugrel Hcl24$1,298
Nitroglycerin38$959
Carvedilol137$914
Spironolactone154$877
Metoprolol Succinate113$855
Atorvastatin Calcium104$772

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$71$57,13248 claims
Boehringer IngelheimJardiance$42$56,96547 claims
Lilly USA, LLCMounjaro$140$16,99616 claims
NovartisEntresto$422$9,48515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 239 acute care providers in Colorado.

Other acute care in Littleton

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →